Literature DB >> 8696724

Postoperative radiotherapy for radically resected N2 non-small-cell lung cancer (NSCLC): randomised clinical study 1988-1992.

M Debevec1, M Bitenc, S Vidmar, T Rott, J Orel, P Strojan, V Kovac.   

Abstract

In the period 1988-1992, 74 consecutive radically resected patients with NSCLC were randomised to postoperative radiotherapy or surgery alone in order to evaluate the influence of postoperative radiotherapy on survival. There were 61 males and 13 females, aged 35-80 years, median 59 years. Their distribution by stage was as follows: pT1N2 = 19, pT2N2 = 54, pT3N2 = one patient; histology: 32 squamous, 32 adeno and 10 large cell carcinomas; surgery: atypical resection in six, lobectomy in 27, bilobectomy in ten, and pneumonectomy in 31 patients. In 27 patients, only one lymph node in a single mediastinal lymph node site was affected; in 31 patients more than one lymph node in one site; in 16 patients more sites were affected. In 35/74 patients radiotherapy of hilar and mediastinal sites with 3000 cGy in 2 weeks was performed. On December 31, 1994, 19 patients (26%) were still alive; 39/55 patients died of the following causes: locoregional failure-10(26%), distant metastases- 25 (64%), other tumor-unrelated causes-four patients (10%). Five-year survival rates did not show statistically significant differences between the irradiated and surgically treated patients only with respect to sex, pTNM stage, histology and frequency of locoregional failure. The number of metastatic mediastinal lymph nodes was the only significant prognostic factor (P < 0.005) in both randomised groups.

Entities:  

Mesh:

Year:  1996        PMID: 8696724     DOI: 10.1016/0169-5002(95)00515-3

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  9 in total

Review 1.  Post-operative radiation therapy.

Authors:  Amaury Paumier; Cécile Le Péchoux
Journal:  Transl Lung Cancer Res       Date:  2013-10

Review 2.  Postoperative radiotherapy for non-small cell lung cancer.

Authors:  Sarah Burdett; Larysa Rydzewska; Jayne Tierney; David Fisher; Mahesh Kb Parmar; Rodrigo Arriagada; Jean Pierre Pignon; Cecile Le Pechoux
Journal:  Cochrane Database Syst Rev       Date:  2016-10-11

Review 3.  A narrative review of postoperative adjuvant radiotherapy for non-small cell lung cancer.

Authors:  Emanuela Olmetto; Marco Perna; Cecilia Cerbai; Michele Aquilano; Marco Banini; Matteo Mariotti; Lorenzo Livi; Vieri Scotti
Journal:  Mediastinum       Date:  2022-03-25

Review 4.  Evidence-based recommendations of postoperative radiotherapy in lung cancer from Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

Authors:  A Gómez; J A González; F Couñago; C Vallejo; F Casas; N Rodríguez de Dios
Journal:  Clin Transl Oncol       Date:  2015-08-18       Impact factor: 3.405

Review 5.  Post-operative radiation therapy (PORT) in completely resected non-small-cell lung cancer.

Authors:  Yelena Krupitskaya; Billy W Loo
Journal:  Curr Treat Options Oncol       Date:  2009-04-22

6.  Postoperative radiotherapy for elderly patients with stage III lung cancer.

Authors:  Juan P Wisnivesky; Ethan A Halm; Marcelo Bonomi; Cardinale Smith; Grace Mhango; Emilia Bagiella
Journal:  Cancer       Date:  2012-02-13       Impact factor: 6.860

7.  Post-operative radiotherapy in NSCLC.

Authors:  L Stewart; S Burdett
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  Propensity score-matching analysis of postoperative radiotherapy for stage IIIA-N2 non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database.

Authors:  Shenhai Wei; Mian Xie; Jintao Tian; Xiaoping Song; Bingqun Wu; Limin Liu
Journal:  Radiat Oncol       Date:  2017-06-13       Impact factor: 3.481

9.  Postoperative Radiotherapy for Patients With Resectable Stage III-N2 Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Tianyu Lei; Jing Li; Hao Zhong; Huibo Zhang; Yan Jin; Jie Wu; Lan Li; Bin Xu; Qibin Song; Qinyong Hu
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.